Conference abstract · 21 Feb 2022
Conference abstractPublished 3 Mar 2022
Targeted and optimized brain drug delivery
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As noted by the World Health Organization, neurological and psychiatric disorders represent the greatest global economic and health burden, where more than 1 billion people are affected and the number is rapidly growing because of the global pandemic. Even though this medical demand has been known for decades, the clinical development pipelines from the pharmaceutical industry are largely deficient, where the most recent commercialized drug for depression was approved by the FDA after three decades of effort by the entire pharmaceutical industry. The lack of clinical advancements is not a strategic failure, but rather a direct result of well-known physiological impedance to drug delivery such as the first-pass effect and the blood-brain-barrier, which either produce significant side effects and/or prevent drugs from reaching the therapeutic target. Thankfully, researchers have discovered viable therapeutic pathways to bypass drug delivery barriers and advancements in nanomedicine will further enable drug delivery, but the greatest potential resides in emerging non-invasive medical device innovations that will provide both targeted and fully optimized drug delivery. This keynote presentation will provide a view into the evolution of drug delivery, clinical dynamics that are motivating emerging classes of therapeutics, existing barriers that could impede advancements and the latest developments that represent great potential for global health transformation. Specific examples of current research and development will be given, with a focus on the role of non-invasive medical devices to produce targeted and optimized drug delivery via local, systemic and nose-to-brain routes. Lastly, the talk will discuss how emerging medical devices can also serve to substantially improve the well-known problem of treatment and medicine adherence, which itself is a $300 billion per year problem and poor adherence will continue to impede even the greatest of advancements in drug delivery and nanomedicine if the problem is not resolved.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 May 2017
Targeted drug delivery system of 5 - Fluorouracil with recombinant epidermal growth factor for brain tumor
Article · 30 Dec 2024
Advances in Blood-Brain Barrier Permeability Modulation for Targeted Drug Delivery in Neuro-Oncology
Conference abstract · 3 Jan 2023
Herbal Nano Particulate Drug Delivery System for Nose to Brain Targeting in the Management of Alzheimer Disease
Opinion · 31 Jul 2022
Prospects for Application in Brain-Targeted Delivery of Traditional Chinese Medicine
More from this journal
The newest in Journal of Neurology and Neuroscience.
Research article · 15 Jul 2025
Oral inhaled cromolyn for mild-to-moderate amyotrophic lateral sclerosis: A randomized, open label phase 2a study
Research article · 15 Jul 2025
Diffuse Intrinsic Pontine Glioma: Unusually Long Survival of 28 Patients (From 3 Years to Over 29 Years) in Phase 2 Studies with Antineoplastons A10 and AS2-1
Short communication · 24 Jun 2025
The Role of High-Pressure Balloon Angioplasty in Treating Intracranial Atherosclerosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Don Turner”

